0.0110USD0.00%Mkt Cap: 9501 USDP/E: —Last update: 2026-05-22
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Olic…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap9.50K USD
Enterprise Value24.11M USD
Revenue (TTM)546.00K USD
Gross Profit1.46M USD
Net Income (TTM)-40.29M USD
Revenue/Share0.6850 USD
Last Price0.0110 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA-0.76
EV/Revenue44.16
P/S0.02
P/B-0.00
EPS (TTM)-48.89
EPS (Forward)-19.85
52W Range
0.00101% of range1.150
52W High1.150 USD
52W Low0.0010 USD
Profitability
Gross Margin46.56%
Oper. Margin-1970.67%
EBITDA Margin0.00%
Profit Margin-1289.25%
ROE526.17%
ROA-99.22%
Growth
Revenue Growth57.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.03M USD
CapEx (TTM)41.00K USD
FCF Margin-3081.27%
FCF Yield-177073.47%
Net Debt24.10M USD
Net Debt/EBITDA-0.76
Balance Sheet
Debt/Equity-4.73
Current Ratio2.42
Quick Ratio2.21
Book Value/Sh-27.2690 USD
Cash/Share15.59 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 13, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.863.79K
Float858.69K
Insiders0.48%
Institutions9.98%
Short Interest
Short Ratio1.0d
Short % Float7.03%
Short % Out.6.96%
Shares Short59.36K
Short (prev mo.)16.17K
Technical
SMA 500.0132 (-16.4%)
SMA 2000.0480 (-77.1%)
Beta0.56
S&P 52W Chg28.31%
Avg Vol (30d)130
Avg Vol (10d)30
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—